title: Risk of hypotony after primary trabeculectomy with antifibrotic agents in a black west African population.
abstract: OBJECTIVE
  To evaluate the risk of hypotony and hypotony maculopathy following trabeculectomy with 5-fluorouracil (5-FU) and mitomycin C (MMC) in a black West African population.
  
  
  METHODS
  One hundred and one eyes of black Ghanaian patients with advanced primary open-angle glaucoma received intraoperative antifibrotic therapy with trabeculectomy as part of two randomized clinical trials. Overall, 57 patients received 5-FU (50.0 mg/ml for 5 minutes) and 44 received MMC (0.5 mg/ml for 3.5 minutes). All cases were performed by one of five surgeons at a single outpatient surgery center.
  
  
  RESULTS
  Two of 101 eyes had a final intraocular pressure (IOP) of less than 5 mm Hg and were thus classified as having hypotony. No patient in either group was noted to develop hypotony-related maculopathy. Overall mean pre- and postoperative IOPs were 30.1 and 15.9 mm Hg, respectively. The patients receiving intraoperative MMC had a lower mean postoperative IOP (14.7 mm Hg) than those receiving 5-FU (first study, 17.1 mm Hg; second study, 16.7 mm Hg; p = 0.05). Mean overall follow-up was 17.7 months and did not differ significantly between the MMC and combined 5-FU groups.
  
  
  CONCLUSIONS
  Hypotony following trabeculectomy supplemented with antifibrotic agents is a rare complication in this population. No eyes in either clinical trial developed hypotony maculopathy, suggesting that the prevalence of this condition is substantially lower in black West Africans than in whites.
authors.affiliation: Stanford University Medical Center, Department of Ophthalmology, CA 94305-5308, USA.
authors.forename: K
authors.initials: K
authors.lastname: Singh
authors.forename: S
authors.initials: S
authors.lastname: Byrd
authors.forename: P R
authors.initials: PR
authors.lastname: Egbert
authors.forename: D
authors.initials: D
authors.lastname: Budenz
mesh_terms: D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects*; D005500:Follow-Up Studies; D005869:Ghana / Q000453:epidemiology; D005902:Glaucoma, Open-Angle / Q000188:drug therapy / Q000208:ethnology / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure; D007432:Intraoperative Period; D008268:Macular Degeneration / Q000453:epidemiology / Q000209:etiology; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects*; D015814:Ocular Hypotension / Q000453:epidemiology* / Q000209:etiology; D009883:Ophthalmic Solutions; D011183:Postoperative Complications; D012189:Retrospective Studies; D012307:Risk Factors; D014130:Trabeculectomy / Q000009:adverse effects*
chemical_list: D009883:Ophthalmic Solutions; D016685:Mitomycin; D005472:Fluorouracil